+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Proton pump inhibitor omeprazole use is associated with low bone mineral density in maintenance haemodialysis patients



Proton pump inhibitor omeprazole use is associated with low bone mineral density in maintenance haemodialysis patients



International Journal of Clinical Practice 63(2): 261-268



Limited studies have shown that proton pump inhibitor (PPI) therapy may decrease bone density or insoluble calcium reabsorption through induction of hypochlorhydria. However, PPI therapy may also reduce bone resorption via inhibition of osteoclastic vacuolar proton pumps. The aim of this study was to determine whether the opposing effects of PPI therapy may cause clinically important alterations in bone mineral densitometry (BMD) parameters in maintenance haemodialysis patients. Sixty-eight maintenance haemodialysis patients were enrolled in this study. Patients were classified into two groups involving users of PPI therapy (omeprazole 20 mg/day, group 1, n = 36 patients) and non-users of acid suppression drugs (group 2, n = 32 patients). Patients had radius, hip and spine BMD assessed by dual-energy X-ray absorptiometry. The mean duration of PPI therapy with omeprazole was 27 +/- 5 months. The users of PPI therapy had lower values of bone mineral density and T-scores at the anatomical regions than non-users of acid suppression drugs. Serum calcium and phosphate levels, calcium-phosphate product and serum intact parathormone levels and the ratio of users of vitamin D therapy were similar among groups. A mutivariable adjusted odds ratio for lower bone density associated with more than 18 months of omeprazole, when all the potential confounders were considered, was 1.31 in the proximal radius, 0.982 in the femur neck, 0.939 in the trochanter and 1.192 in the lumbal spine. The present data suggest that PPI therapy should be cautiously prescribed in maintenance haemodialysis patients, especially with lower BMD values.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 055260241

Download citation: RISBibTeXText

PMID: 19196364

DOI: 10.1111/j.1742-1241.2008.01883.x


Related references

Proton-pump inhibitor use is not associated with osteoporosis or accelerated bone mineral density loss. Gastroenterology 138(3): 896-904, 2010

Su1063 The Bone Mineral Density and Qol Between Proton Pump Inhibitor User and Nonuser. Gastroenterology 144(5): S-390, 2013

Proton-Pump Inhibitor Use Is Not Associated With Osteoporosis or Accelerated Bone Mineral Density Loss. Yearbook of Medicine 2010: 442-443, 2010

Efficacy of the four weeks treatment of omeprazole plus mosapride combination therapy compared with that of omeprazole monotherapy in patients with proton pump inhibitor-refractory gastroesophageal reflux disease: a randomized controlled trial. Clinical and Experimental Gastroenterology Volume 12: 337-347, 2019

Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: results from the Women's Health Initiative. Archives of Internal Medicine 170(9): 765-771, 2010

Efficacy of alfacalcidol and alendronate on lumbar bone mineral density in osteoporotic patients using proton pump inhibitors. Biomedical Reports 5(2): 165-170, 2016

Proton pump inhibitors use and change in bone mineral density. International Journal of Rheumatic Diseases 19(9): 864-868, 2017

Mo1082 The Effect of Three Months use of Proton Pump Inhibitors on Bone Mineral Density, Bone Markers and Calcium Metabolism in Men With Gastroesophageal Reflux Disease. Gastroenterology 142(5): S-590, 2012

Correlation of Bone Mineral Density Scores and Proton Pump Inhibitors Use in the Elderly. Current Rheumatology Reviews 12(2): 162-166, 2017

Fracture risk and bone mineral density reduction associated with proton pump inhibitors. PharmacoTherapy 32(1): 67-79, 2012

Effect of long-term proton pump inhibitors on bone mineral density. La Tunisie Medicale 96(3): 193-197, 2018

Pharmacokinetic interaction between the proton pump inhibitor omeprazole and the HIV protease inhibitor indinavir. Aids 12(15): 2080-2082, 1998

Omeprazole: the first proton pump inhibitor. Medicinal Research Reviews 10(1): 1-54, 1990

Omeprazole, a proton pump inhibitor, improves residual steatorrhoea in cystic fibrosis patients treated with high dose pancreatic enzymes. European Journal of Pediatrics 162(11): 760-763, 2003

The proton pump inhibitor, omeprazole, but not lansoprazole or pantoprazole, is a metabolism-dependent inhibitor of CYP2C19: implications for coadministration with clopidogrel. Drug Metabolism and Disposition: the Biological Fate of Chemicals 39(11): 2020-2033, 2012